ANTI-LEUKEMIC BETA-GLYCOSYL C-NUCLEOSIDES

Abstract: Beta-glycosyl C-nucleoside compound of the formula (Excluded 2-deazaoxoformycin) and HCL salts thereof wherein X is NR₁₀, S or O R₁₀ is H or alkyl with 1 to 6 carbon atoms. R₁ is or SR₈, or OR₈ wherein R₆, R₇ and R₈ are independently selected from H or alkyl of 1 to 6 carbon atoms; or R₂ is H, NH₂, SR₁₂, or OR₁₂ wherein R₁₆, R₁₁ and R₁₂ are independently selected from H or alkyl of 1-6 carbon atoms; R₃ is OH, SR₁₃, or OR₉; R₄ is OH, SR₁₄, or OR₁₅; R₉, R₁₃, R₁₄ and R₁₅ are individually selected from C₁-C₆ alkyl and C₁ to C₆ acyl; R₅ is OH or H, R′₅ is OH or H with the proviso that at least one of R₅ or R′₅ is H.

Description: The invention described herein was made in the course of work under a grant or award from the Department of Health, Education, and Welfare. BACKGROUND This invention relates to an anti-cancer agent and process for preparing for same. More particularly, this invention relates to beta-glycosyl C-Nucleoside compounds which have been found to inhibit the growth of leukemic cells. The compounds have been demonstrated to have antitumor activity and appear to have some anti-viral activity. Methods for making N-Nucleosides similar to the C Nucleosides, which are the subject of this invention, are well known and well practiced. These techniques basically involve fusing an appropriate sugar to an appropriate base to form the required compound. These techniques cannot be applied to C-Nucleosides because of the low reactivity of the carbon site when compared with the nitrogen site. To form C-Nucleosides, it has been found convenient to start with an appropriately substituted sugar moiety and "build" the desired base. However, known schemes for accomplishing this are difficult to follow and have only limited applicability because of the reagents used (see for example Gupta et al Abstract No. 40, 175 A. C. S. National Meeting, Anaheim, California, March 13-17, 1978). Another procedure was also applied to the synthesis of a closely related compound to the inventive compounds, in Lim et al. Tetrahedron Letters, Volumn 21, pp 1013-1016 (1980). However, this compound has been found to have essentially no antitumor activity. For comparison, this compound is included in Table 1 showing relative inhibition activity for various inventive compounds (X-NH, R1=OH). SUMMARY The present invention provides compounds having antitumor activity and which are useful in inhibiting leukemic cells. The compounds are "built" by forming the base on a blocked sugar beta-ribofuranosyl C-Glycoside substituted by beta-dimethylaminoacrylonitrile. This starting material can be prepared by following the method of Silvano De Bernardo and Manfred Weigele, J. Org. Chem. Vol. 42, No. 1, pp 109-112 (1977). The reaction proceeds first by hydrolyzing the dimethylamino group to a hydroxyl group under conditions which do not affect the blocking groups; forming a five-membered heterocyclic ring; separating alpha and beta isomers; and forming a pyrimidine ring fused with the five-membered ring, from the beta isomer. This sugar is then unblocked, usually with hydrochloric acid, to form the compound or its corresponding hydrochloric acid salt. EMI3.1 <SEP> TABLE <SEP> 1 <tb> # <SEP> IN <SEP> VITRO <SEP> ACTIVITY <SEP> (IRD50'S <SEP> IN <SEP> G/ML) <SEP> OF <tb> C-NUCLEOSEIDES <SEP> IN <SEP> MOUSE <SEP> AND <SEP> HUMAN <SEP> LEUKEMIC <SEP> CELL <SEP> LINES <tb> <SEP> P=815 <SEP> L=1210 <SEP> RAJI <SEP> ALL- <SEP> HL-60 <tb> <SEP> CCRF-CEM <tb> X=NH <tb> <SEP> R1=OH, <SEP> R2=H <SEP> > 10(0%) <SEP> > 100 <SEP> > 100 <SEP> > 100 <SEP> > 100 <tb> R2=H <tb> <SEP> R1=SH, <SEP> " <SEP> 5; ;6 <SEP> - <SEP> - <SEP> - <SEP> R3=R4= <tb> <SEP> R1=SMe, <SEP> " <SEP> 0.3 <SEP> - <SEP> - <SEP> - <SEP> R5=OH, <tb> <SEP> R1=NH2, <SEP> " <SEP> 0.001 <SEP> 0.0008 <SEP> 0.002 <SEP> 0.0008 <SEP> 0.0003 <tb> R5'=H <tb> X=S <tb> <SEP> R1=OH, <SEP> R2=H <SEP> 2.5 <SEP> 3.3 <SEP> 4.2 <SEP> 0.9 <SEP> 0.4 <tb> R2=H <tb> <SEP> R1=SH, <SEP> " <SEP> 0.5 <SEP> 0.6 <SEP> 0.9 <SEP> 1.6 <SEP> 0.4 <tb> R3=R4= <tb> <SEP> R1=SMe, <SEP> " <SEP> 0.03 <SEP> 0.07 <SEP> 0.03 <SEP> 0.006 <SEP> 0.008 <tb> R5=OH, <tb> <SEP> R1=NH2, <SEP> " <SEP> 0.0003 <SEP> 0.0006 <SEP> 0.002 <SEP> 0.0005 <SEP> 0.0005 <tb> R5'=H <tb> EMI4.1 TABLE 2 IN VIVO ACTIVITY OF C-NUCLEOSIDES IN MICE EMI4.2 <tb> C-NUCLEOSIDE <SEP> LINE <SEP> SCHEDULE <SEP> e <SEP> DOSE <SEP> % <SEP> ILS <SEP> <tb> <SEP> (MG/KG) <tb> X=NH <SEP> L-1210/0 <SEP> QD <SEP> x <SEP> 5,D1&commat; <SEP> <SEP> 0.5 <SEP> 9.1 <tb> R1=NH2, <SEP> R2=H <SEP> " <SEP> Q4D <SEP> x <SEP> 3,D1&commat; <SEP> 0.25 <SEP> <SEP> 17.0 <tb> R3=R4=R5=OH <tb> <SEP> L-1210/MP <SEP> Q4D <SEP> x <SEP> 3,D1&commat; <SEP> 0.4 <SEP> 71.8 <tb> R5'=H <tb> <SEP> P-815/ARA <SEP> C <SEP> Q4D <SEP> x <SEP> 3,D1 <SEP> &commat; <SEP> 0.7 <SEP> 30.8 <tb> <SEP> " <SEP> " <SEP> " <SEP> " <SEP> 0.4 <SEP> 19.8 <tb> X=S <tb> R1=SCH3, <SEP> R2=H <SEP> P-815/0 <SEP> QD <SEP> x <SEP> 2/Q2D <SEP> x <SEP> 3 <SEP> &commat; <SEP> 60 <SEP> 71.4 <tb> R3=R4=R5=OH <SEP> n <SEP> Q4D <SEP> x <SEP> 4,D1 <SEP> e <SEP> 40 <SEP> 56.3 <tb> R5'=H <tb> DESCRIPTION The beta-glycosyl C-nucleoside compounds of the present invention have been shown to have anti-leukemic activity using usual techniques of the art. The results of these tests are summarized in Table 1. In addition, in vivo antitumor activity has been shown as summarized in Table 2. It is noted that the first compound in Table 1 is the compound reported in Lim et al (supra). This compound shows a lack of activity. Similar tests were also run on certain alpha-glycosyl nucleosides analogous to the inventive beta-glycosyl compounds, however these were found to be without activity. The following preparative examples illustrate the presently preferred method of synthesizing the compounds of the present invention. (By lower alkyls is meant straight or branched alkyls of up to 6 carbon atoms.) PREPARATIVE EXAMPLE FOR PYRROLO (3,2-d) PYRIMIDINE ADENOSINE ANALOG EMI6.1 2-(2',3'-0-Isopropylidene-5'-0-Trityl-D-ribofuranosyl) -3- (N-Cyano-methylene) -aminoacrylonitrile p3 To a solution of 36g (70mmol,) of dimethylamino acrylonitrile Q in chloroform (720 ml) was added a solution of trifluoroacetic acid (18 ml) in water (1.2 1.). The mixture was stirred vigorously for 16 hours at room temperature and the organic layer was washed thoroughly with water and dried over anhydrous sodium sulfate filtered and evaporated to dryness in vacuo to afford 2-formylacetonitrile 0 Without purification, 0 was dissolved in methanol (420 ml) and to this was added anhydrous sodium acetate (8.6 g, 105 mmol.), aminoacetonitrile hydrochloride (8.6 g, 93 mmol.) and water (15 ml). The clear solution was stirred for 20 hours at 250 C. The solution was then diluted with chloroform (1 liter) and the mixture was poured into ice (300 g). The organic layer was separated, washed several times with water, dried over sodium sulfate and evaporated to dryness. This afforded a white solid to which was added diethyl ether. After chilling in an ice-bath the white solid was collected by suction filtration to give 30 g (81.5%) of 2-(2', 3'-0-Isopropylideue-5'-0-Trityl-D-ribo-furanosyl)-3- (N-cyanomethylene)-amino acrylonitrile 0 as an alpha, beta anomeric mixture. The structure was confirmed by EMI7.1 4-(2,3,-O-Isopropylidene-5-O-Trtyl-ss-(and &alpha;-) D-ribo furanosyl) -2-cyano-3-aminopyrrole To a solution of compound o (10.43 g, 20 mmol.) in dichloromethane (100 ml) at 0 C was added DBN (1,5 diazabicyclo[4,3,0] non-5-ene) (4.96 g, 40 mmol.) followed by a solution of ethyl chloroformate (3.42 g, 32 mmol.) in dichloromethane (20 ml). After completion of the transformation to the N-carboethoxy derivative 4 (approximately 1 hour), an additional equivalent of DBN (2.48 g, 20 mmol.) was added and the reaction mixture was stirred at 25 C for 20 hours and evaporated to dryness. Chromatographic purification of the residue on silica gel (chloroform/ethyl acetate; 9/1) afforded the N-carboethoxy pyrrole 0 (&alpha;,ss-anomeric mixture) as a white foam (10 g, 84 % from ). The structure was confirmed by CHN elemental analysis and NMR spectroscopy. Intermediate 5 (10 g, 16.8 mmol.) was dissolved in methanol (60 ml) to which was added sodium carbonate (178 mg, 1.7 mmol.). The mixture was stirred at room temperature for 50 minutes and filtered. The filtrate was evaporated and the residue was purified by flash chromatography on silica gel (toluene/ethyl acetate; 8/1) to give 5.40 g (61 % from 0 of the desired beta-isomer z and 2.26 g (26 % from 0 ) of the alpha-isomer (7 . Beta-isomer z : MP. 170-172 C (Ethyl acetate/ diethyl ether). Structure was confirmed by C,H,N elemental analysis and NMR spectra. Alpha-isomer z 0 : MP. 176 C (dec) (Acetone/Hexanes) structure was confirmed by C,H,N elemental analysis and NMR spectra. EMI8.1 7-(ss-D-Ribofuranosyl)-4-amino-pyrrolo [3,2-d] pyrimidine 9 A mixture of the beta-3-amino-4-cyanopyrrole 6 (3.15 g, 6 mmol.) in absolute ethanol (25 ml) was heated to reflux for 4-1/2 hours and evaporated to dryness in vacuo. The residue was dissolved in ethyl acetate, and the solution was washed with water then brine and finally evaporated to dryness. Chromatographic purification of crude z on silica gel (dichloromethane/methanol; 20/1 then 10/1) afforded pure as a white solid (3.1 g, 93.6 %). Structure was confirmed by C,H,N element mass spectroscopy NMR and Wspectroscopy. To a solution of the blocked C-nucleoside ( (653 mg, 1.2 mmol.) in methanol (5.5 ml) was added 7.2 ml of a 12.6 9s solution of hydrogen chloride in methanol. The reaction mixture was stored at 200 C for 2 hours then treated with diethylether (1-2 ml) and cooled in an ice bath. The resulting crystalline precipitate was collected by filtration to give "9-deazaadenosine" hydrochloride 0 (300 mug. 74 96). Recrystallization from ethanol afforded an analytically pure sample (mp: 179-183 C). Analysis calculated for: C:43.63; H:4.99; N:18.49; Cm:11.72. Found: C:43.68; H:4.97; N:18.43; Cl:11.75. Structure was further confirmed by NMR and UV spectroscopy. This procedure is applicable, inter alia to: 7- (ss-D-Ribofuranosyl)-2,4-diamino-pyrrolo[3,2-d] pyrimidine by substitution of guanidine carbonate for formamidine acetate in step 7-(B-D-Ribofuranosyl)-4-amino-5-methyl (or lower alkyls)- pyrrolo[3,2-d] pyrimidine by substitution of N-Methyl (or lower alkyl) aminoacetonitrile. By utilization of the general procedure (J. Am. Chem. Soc, 1981 (103 pp. 932-933)) for conversion of ribonucleosides to 2'-deoxynucleosides the following 7-(2'-Deoxy-ss-D-ribofuranosyl)-4-amino-pyrrolo [3,2-d] pyrimidine. 7-(2'-Deoxy-ss-D-ribofuranosyl)-2,4-diamino-pyrrolo [3, 2-dj pyrimidine. 7-(2'-Deoxy-ss-D-ribofuranosyl)-4-amino-5-methyl (or lower alkyls)-pyrrolo [3,2-d] pyrimidine. PREPARATIVE EXAMPLE FOR THIENO ,2-11 -(and FURO (3, 2-i) PYRIMIDINE ADENOSINE ANALOGS EMI10.1 3-Methanesulfonyloxy-2-(2',3'-O-isopropylidene-5'-Otrityl-D-ribofuranosyl)-acrylonitrile. Hydrolysis of 24 am (47 mmol.) of dimethylamino acrylonitrile 1 as described previously afforded the corresponding crude 2-formyl acetonitrile derivative 0 . Without purification 2 was dissolved in 160 ml of chloroform containing 8.30 ml of triethylamine and treated dropwise with a solution of 4.22 ml (54 mmol.) of methanesulfonsyl chloride in 160 ml of chloroform at 0 C with efficient stirring. After one hour at 00 C the reaction mixture was diluted to 500 ml with chloroform and washed well with brine. The organic layer was dried over sodium sulfate and evaporated to dryness to give a crude anomeric mixture of 3 obtained as a foam (22 gm). Purification and separation by chromatography of a small sample afforded pure anomers which were readily identified by NMR spectrocopy. The crude material was of satisfactory purity to be utilized EMI11.1 4-(2',3'-O-Isopropylidene-5'-O-trityl-ss-(and &alpha;-) D-ribofuranosyl)-3-amino-2-cyanothiophene 5 and To a solution of intermediate (2) (20 g, obtained from the previous step) in 430 ml of absolute ethanol was added acetylthioacetonitrile (8 g, 70 mmol.) and anhldrous sodium carbonate (8 g, 70 mmole.). The reaction mixture was heated to reflux under N2 for 7 hours and evaporated to dryness in vacuo. The residue was partitioned between chloroform and water (300 ml each) and the organic layer washed again with water. The chloroform solution was then dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The residue containing the a-ss-anomeric mixture of and 6 was purified by column chromatography on silica gel (Toluene) to give 5.6 gm (24.5 % from in the previous step) of the 3-amino-2-cyanothiophene ss-C-nucleoside ) and 2.5 gm (11 % from (i) ) of the corresponding a-C-nucleoside 6 . Both were obtained as syrup. Their structure was confirmed by elemental analysis and NMR spectroscopy. EMI12.1 7-(23-o-Isopropylidene-5l-O-trityl-D-l)-ribofuranosyl) -4-ainino-thieno [3,2-d] pyrimidine (i) A solution of 0 (1.2 gm, 2.2 mmol.) in 30 ml of absolute ethanol was heated to reflux and to this was added in several portions 7 gm of formamidine acetate (67 mmol.) over a period of 7 days. The solvent was then removed in vacuo and the residue extracted with chloroform. The chloroform solution was then washed with water, dried over anhydrous sodium sulfate and evaporated to dryness. The crude material containing 7 was purified by column chromatography on silica gel (chloroform-methanol: 20/1) to give the blocked thieno [3, 3-d] pyrimidine (g (1.01 gm, 80 % from as a foam. The structure was confirmed by elemental analysis and NMR spectroscopy. EMI12.2 7-(D-D-ribofuranosyl)-4-amino-thieno[3,2-d]pyrimidine 8 A mixture of the blocked C-nucleoside Q (200 mg, 0.35 mmole.) and 4 ml of a 12 % solution of hydrogen chloride in methanol was stirred at room temperature for 10 minutes. Diethylether (15 ml) was then gradually added to precipitate as an amorphous solid which slowly crystallizes. Filtration and washing with diethylether finally affords 98 mg (85 %) of z as 0 a dihydrochloride salt m. p. 154-155 C. Elemental Analysis Calculated for: C:37.08; H:4.24; N:11.79; S:8.99; Cl:19.90. Found: C:37.74; H:4.17; 11.89; S:9.30; Cm:20.40. The structure was also confirmed by NMR spectroscopy. The furo [3,2-d] pyrimidine compounds are prepared in an analogous manner, as shown by the following reaction scheme when compared with this preparative example. SEQUENCE FOR THE FURO [3,2 d] PYRIMIDINE ADENOSINE ANALOG EMI14.1 This procedure is applicable inter alia to 7-(ss-D-Ribofuranosyl)-2,4-diamino-thieno [3,2-d] pyrimidine and 7-(ss-D-Ribofuranosyl)-2,4-diamino-furo[3,2-d] pyrimidine by substitution of guanidine carbonate for formamidine acetate. By utilization of the general procedure (J. Am. Chem. Soc., 1981 (103 pp 932 - 933)) for conversion of ribonucleosides to 2'-deoxynucleosides the following 7-(2'-Deoxy-ss-D-ribofuranosyl)-4-amino-thieno[3,2-d] pyrimidine 7-(2'-Deoxy-,B-D-ribofuranosyl)-4-amino-furo[3,2-d] pyrimidine 7-(2'-DeOxy-ss-D-ribofuranosyl)-2,4-diamino-thieno[3,2-d] pyrimidine 7-(2'-Deoxy-ss-D-ribofuranosyl)-2,4-diamino-furo[3,2-d] pyrimidine EMI16.1 4-(2',3'-O-Iospropylidene-5'-O-trityl-ss-(and &alpha;-) D-ribofuranosyl)-3-amino-2-carboxyamido-thiophene 0 ana ¯ To a suspension of 3-mesyloxy acetonitrile 3 (6 gm, 10.7 mmol, prepared by the method above described) in 180 ml of absolute ethanol was added mercaptocetamide (1.5 g, 16.4 mmol) and anhydrous sodium carbonate (1.7 gm, 16.03 mmol). The reaction mixture was heated to reflux with stirring for 18 hours under a nitrogen atmosphere, allowed to cool to room temperature and filtered. The filtrate was evaporated to dryness in vacuo and the residue containing the isomers 5 and 6 chromatographed on a column of silica gel with toluene-ethyl acetate (20:1). This separation afforded pure 3-amino 2-carboxamido-ss-isomer ( ) as a foam (2.62 gm, 40 % from ( ) and the pure a-isomer 6 also as a foam (2.94 gm, 45 % from 3 ). The structure of each was confirmed by elemental analysis and NMR spectroscopy. EMI17.1 7-(2',3'-0-isopropylidene-5'-¯-trityl-ss-D-ribOfuranosyl) -3H-4-oxo-thieno[3,2-d]-yprimidine. 7 To a suspension of 3-amino-2-carboxamido-thiophene 0 (3.5 gm, 6.29 mmol) in 20 ml of triethylorthoformate was added 1 gm of finely ground molecular sieve (4 ). The reaction mixture was heated at 950 C and stirred for 24 hours. After cooling to room temperature, it was filtered and to the clear filtrate was added 10 ml of petroleum ether (40-60 ) to precipitate compound 0 as a solid. This was collected by filtration, pressed into a cake, washed with petroleum ether and dried in vacuo. This procedure afforded 0 (2 gm, 56 % . as a white powder, mp 128-130 C The structure was confirmed by elemental analysis and by NMR spectroscopy. EMI17.2 7-(ss-D-Ribofuranosyl)-3H-4-oxo-thieno[3,2-d]pyrimidine monohydrochloride 8 A mixture of compound 3 (5.8 gm, 10.24 mmol) in 50 ml of a 6 % solution of hydrogen chloride in methanol was stirred at 20 C for 20 minutes and 120 ml of dietyl ether was then added to gradually form a white precipitate. After one hour, the crystalline C-nucleoside monohydrochloride 8 was filtered and washed with ether to give 2.56 gm (88 %) of the desired product, mp 211-214 C. Anal. Calcd: C:41.19, H:4.08, N:8.73, S:9.99 Found: C:41.59, H:4.10, N:8.65, S:9.85 Structure was confirmed by NMR spectroscopy. EMI18.1 7-(2',3',5'-tri-0-acetyl-ss-D-ribofuranosyl)-3H-4-oXo- thieno[3,2-d]pyrimidine To a solution of compound 8 (1.5 gm, 5.28 mmol) in anhydrous pyridine (5 ml) was added acetic anhydride (5 ml) at 0 C. After one hour the mixture was partitioned between chloroform (100 ml) and water (100 ml). The organic layer was washed with water (10d ml), dried over anhydrous Na2-S04 and evaporated to dryness in vacuo. The residue containing 9 was purified by chromatography on a silica gel column with chloroformmethanol (40:1) to give 1.61 gm (75 96) of the triacetate as as a colorless syrup. The structure was confirmed by elemental analysis and NMR spectroscopy. EMI19.1 7-(2',3',5'-Tri-O-acetyl-ss-D-ribofuranosyl)-3H-4-thiono- thieno[ 3, 2-d]pyrimidine (10) To a solution of 9 (3 gm, 7.31 mmol) in 40 ml of dry dioxane heated to reflux was added 3 gm of phosphorous pentasulfide in portions (200 mg each) over a period of 1.5 hours. Heating was continued until thin layer chromatography (chloroform/methanol: 10/1) indicated that the reaction was completed. The solvent was removed in vacuo and the residue containing 10 was purified by chromatography on a column of silica gel (chloroform/methanol: 20/1) to give the thieno-pyrimidine thione i) in pure form (2.62 gm, 84 %) as a foam. The structure was confirmed by NMR spectroscopy. EMI19.2 7-(ss-D-ribofuranosyl)-3H-4-thiono-thieno[3,2-d] pyrimidine7 A solution of triacetate Go (2.02 gm, 4.74 mmol) in 40 ml of 0.1 N sodium methoxide in methanol was stirred at 200 C for 1 hour. The final solution was neutralized with IRC-50 (H ) ion exchange resin, filtered and the filtrate evaporated to dryness in vacuo. The residue was dissolved in water and the aqueous solution washed with chloroform. The aqueous layer was lyophilized to give 1.36 gm (95 %) of pure 7-(ss-D-ribofuranosyl)-3H -4-thiono-thieno[3,2-d]-yprimidine as a powder. The structure was confirmed by NMR spectroscopy. EMI20.1 Thieno 3,2-d pyrimidine analog of Methylthio urine riboside 7-(ss-D-Ribofuranosyl)-4-methylthio-thieno[3,2-d] pyrimidine To a solution of triacetate 10 (350 mg, 0.82 mmol) in a mixture of 3 ml of methanol and 3.3 ml of methyl iodide was added 10 ml of 0.1 N aqueous sodium hydroxide and the reaction mixture was stirred at room temperature for one hour. During this period, the product desired 12 precipitated. This was collected by filtration, washed with methanol then chloroform to afford 255 mg (98 %) of 7-(ss-D-ribofuranosyl)-4- methylthio-thieno[3,2-d]pyrimidine as a crystalline (white needles) material. One recrystallization from boiling methanol afforded the analytical sample: mp 226-228 C, Anal. Calcd. for: C: 45.84, H: 4.48, N: 8.90, S:20.39 Found: C: 45.89, H: 4.51, N: 8.88, S:20.25 The structure was confirmed by NMR spectroscopy.

Claims: What is claimed is: 1. Beta-glycosyl C-nucleoside compound of the formula wherein EMI22.1 X is NR10, S or O R10 is H or alkyl with 1 to 6 carbon atoms R1 is EMI22.2 or SR8, or OR8 wherein R6, R7 and R8 are independently selected from H or alkyl of 1 to 6 carbon atoms; or R2 is H, EMI22.3 SR12, or OR12 wherein R16, R11 and R12 are independently selected from H or alkyl of 1-6 carbon atoms; R3 is OH, SR13, or ORg; R4 is OH, SR1v, or OR15; R9, R13, R14 and R15 are individually selected from C1 - C6 alkyl and C1 to C6 acyl; R5 is OH or H, R5 is OH or H with the proviso that at least one of R5 or R5' is H; Excluding 2-deazaoxoformycin; and HCl salts thereof. 2. The compound of claim 1 wherein X = NR10 R3 = R4 = R5 = OH R5 = H; and R10 =H. 3. The compound of claim 2 wherein R1 is OH and R2 is NH2. 4. The compound of claim 1 wherein X = S R3 = R4 = R5 = OH = H. 5. The compound of claim 1 wherein X = O R3 = R4 = R5 = OH, and R5 = H. 6. The compound of claim 1, 2, 4 or 5 wherein R1 is NH2, NHCH3, SH, or SCH3. R2 is H or NH2. 7. The compound of claim I wherein X = N R3 = R4 = OH R5 = R5' = H R10 is H. 8. The compound of claim 1 wherein XD = S R3 = R5 = OH R5 = R5' = H. 9. The compound of claim 1 wherein X=O R3 = R4 = OH = R5' = H. 10. The compound of claim 7, 8 or 9 wherein R1 = NH2 or NHCH3, R2 = H or NH2. 11. The compound of claim 1 designated 7-(ss-D-Ribofuranosyl)-4-amino-pyrrolo[3,2-d] pyrimidine. 12. The compound of claim 1 designated 7-(ss-D-Ribofuranosyl)-2,4-diamino-pyrrolo [3,2-d] pyrimidine. 13. The compound of claim 1 designated 7- -Ribofuranosyl) -4-amino-5-methyl*-pyrrolo [3,2-d] pyrimidine. 14. The compound of claim 1 designated 7-(ss-D-Ribofuranosyl)-4-amino-thieno [3,2-d] pyrimidine. 15. The compound of claim 1 designated 7-(ss-D-Ribofuranosyl)-2,4-diamino-thienot3,2-d] pyrimidine. Methyl may be replaced by other lower alkyls. 16. The compound of claim 1 designated 7-(2Deoxy-p-D-ribofuranosyl)-4 ino-thieno[3,2-d ] pyrimidine. 17. The compound of claim 1 designated 7-(2)-Deoxy-ss-D-ribofuranosyl)-2,4-diamino-thieno [3, 2-d] pyrimidine. 18. The compound of claim 1 designated 7-(2'-Deoxy-ss-D-Ribofuranosyl)-4-amino-pyrrolo t3,2-d] pyrimidine. 19. The compound of claim 1 designated 7-(2'-Deoxy-ss-D-Ribofuranosyl)-2,4-diamino-pyrrolo [3,2-d] pyrimidine. 20. The compound of claim 1 designated 7-(2'-Deoxy-gS-D-Ribofuranosyl)-4-amino-5-methyl- pyrrolo g3,2-dy pyrimidine. 21. The compound of claim 1 designated 7-(ss-D-Ribofuranosyl)-4-amino-furo[3,2-d] pyrimidine. 22. The compound of claim 1 designated 7-(ss-D-Ribofuranosyl)-2,4-diamino-furo[3,2-d] pyrimidine 23. The compound of claim 1 designated 7-(2'-Deoxy-p-D-ribofuranosyl)-4-amino-furo[3,2-d] pyrimidine. 24. The compound of claim 1 designated 7-(2'-Deoxy-ss-D-ribofuranosyl)-2,4-diamino-furo [3,2-d] pyrimidine. methyl may be replaced by other lower alkyls. 25. The compound of claim 1 selected from 7-(ss-D-Ribofuranosyl)-4 methyl*amino-pyrrolo [3,2-d, pyrimidine, 7-(ss-D-ribofuranosyl)-4 mercapto-pyrrolo[3,2-d] pyrimidine, 7-(ss-D-ribofuranosyl)-4 methylthio-pyrrolo[3,2-d] pyrimidine, 7-(ss-D-ribofuranosyl)-2-amino-4-mercapto-pyrrolo [3,2-d] pyrimidine, 7-(ss-D-Ribofuranosyl)-4-methyl*amino-thieno [3,2-d] pyrimidine, 7-(ss-D-Ribofuranosyl)-4-mercapto-thieno[3,2-d] pyrimidine, 7-(ss-D-Ribofuranosyl)-4-methyl* thio-thieno[3,2-d] pyrimidine, 7-(ss-D-Ribofuranosyl)-4-oxo-3H,5H-thieno[3,2-d] pyrimidine (Tautomeric form of the 4 hydroxy derivative) 7-(ss-D-Ribofuranosyl)-2-amino-4-oxo-3H,5H-thieno [3,2-d3 pyrimidine (Tautomeric form), 7-(ss-D-Ribofuranosyl)-2-amino-4-mercapto-thieno [3,2-d3 pyrimidine, 7-(2'-Deoxy-ss-D-ribofuranosyl)-4-methyl*amino thieno[3,2-d] pyrimidine, 7-(2'-Deoxy-ss-D-ribofuranosyl)-4-oxo-3H,5H-thieno [3,2-d] pyrimidine (Tautomeric form of the 4 hydroxy derivative). 7-(2'-Deoxy-B-D-ribofuranosyl)-2-amino-4 oxo-3H, 5H-thieno[3,2-d] pyrimidine (Tautomeric form), 7-(2'-Deoxy-ss-D-Ribofuranosyl)-4-methyl*amino pyrrolo[3,2-d] pyrimidine, 7-(-D-Ribofuranosyl)'-4-methyl+amino-furoE3,2-d] pyrimidine, 7-(ss-D-Ribofuranosyl)-4-mercapto-furo[3,2-d] pyrimidine, +Methyl may be replaced by other lower alkyls. 7-(ss-D-Ribofuranosyl)-4-methyl thio-furo[3,2-d] pyrimidine, 7-(ss-D-Ribofuranosyl)-2-amino-4-mercapto-furo [3,2-d jpyrimidine, 7-(2'Deoxy-ss-D-ribofuranosyl)-4-methyl amino- furo[3,2-d] pyrimidine. 26. In a method for preparing the beta-glycosyl C-nucleo side compound of claim 1, the steps of (a) providing a blocked sugar ss-ribofuranosyl C glycoside substituted by B-dimethylaminoacryloni- trile; (b) hydrolyzing the dimethylamino group to a hydroxyl group under conditions which do not effect the blocking groups; (c) forming a five membered heterocyclic ring either by reaction of said hydroxyl group with N-alkyl or aminoacetonitrile followed by a ring closure, or by mesylation of said hydroxyl group, followed by substitution of an oxygen or sulfur containing synthon for the mesyl group and finally by ring closure; (d) separating alpha and beta isomers; (e) forming a pyrimidine ring fused with said five membered ring, from the beta isomer; and (f) unblocking the sugar. 27. The method of claim 26 wherein said synthon is selected from EMI27.1 HO-CH,-CONH, wherein R is methyl or ethyl and R' is methyl or ethyl. Methyl may be replaced by other lower alkyls. 28. A method of inhibiting leukemic cell reproduction comprising contacting said cells with an effective amount of the compound of claim 1.

Inventors: BURCHENAL, JOSEPH H., KLEIN, ROBERT S., LIM, MU-ILL, REN, WUYUN
Applicants: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Application year: 1982
Main classification: C07D487
IPC codes: C07D493, C07D491, A61K31, A61P35, C07D487, C07D519, C07D495